Biofrontera (BFRI) Capital Expenditures Growth (1y) (2022 - 2025)
Biofrontera (BFRI) Capital Expenditures Growth (1y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -21.54% |
| 10 | Biofrontera | 10.73 Mn | 4.32 Mn | 14.09 Mn | -200.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -200.00% |
| Jun 30, 2025 | 102.08% |
| Mar 31, 2025 | -94.74% |
| Dec 31, 2024 | 111.11% |
| Jun 30, 2024 | -104.13% |
| Mar 31, 2024 | 307.14% |
| Dec 31, 2023 | -1,000.00% |
| Jun 30, 2023 | 3,651.61% |
| Mar 31, 2023 | 180.00% |
| Dec 31, 2022 | -88.89% |
| Sep 30, 2022 | 200.00% |